www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Two new lung cancer medicines offer hope

By Zhou Wenting in Shanghai | China Daily | Updated: 2018-04-20 09:20
Share
Share - WeChat

Late-stage lung cancer patients who have built up a tolerance to some drugs may have new hope thanks to two domestically developed medicines, doctors from Shanghai Chest Hospital said on Thursday.

Clinical trials showed that by using a small molecular, multi-targeted drug called anlotinib hydrochloride, the lives of lung cancer patients could be prolonged an average of 50 percent over patients receiving placebos. They survived another 3.3 months on average, said Han Baohui, who led the clinical trials that involved 437 patients at 34 health centers and hospitals nationwide.

The treatment, which inhibits the growth of tumors and the development of surrounding blood vessels, will be available to the general public this year, he said.

Han is director of respiratory medicine at the hospital, which carries out some of the country's most advanced lung cancer diagnoses and treatments.

"One headache for doctors around the world is that there is no guide for how to prescribe medicines for late-stage patients who build up tolerance to various medicines after taking them for long periods," Han said, adding that most doctors prescribe based on what's worked for them in the past.

The new treatment "may become a standard in our country as a viable prescription for these patients", he said, adding that the cost of taking the medicine is estimated at around 10,000 yuan ($1,600) per month.

According to China's National Cancer Center, 4.29 million new cancer patients are diagnosed in the country annually, with lung cancer ranked first among all cancers in both rate of occurrence and mortality.

Another drug that will soon be used in final-stage clinical trials - fruquintinib - also showed promising results, said Lu Shun, director of oncology at Shanghai Chest Hospital.

In previous clinical trials of 91 patients nationwide, the three-and six-month survival rates of those who were given the new treatment - one that also inhibits vascular development around tumors - were 90 percent and 67 percent, respectively, compared with 73 percent and 58 percent among those who received placebos.

A research paper on the subject was published in Journal of Clinical Oncology in the United States in March.

Lu said that since 2016 his department has also conducted the country's first research on standards of medical treatment for Chinese lung cancer patients who hope to use immunotherapy - a pioneering approach to combating certain cancers.

More than 200 patients have participated in national research to identify the biological characteristics that make some people more receptive to the breakthrough therapy.

Immunotherapy relies mainly on antibodies that suppress certain genes acting as a braking mechanism in the immune response. With that therapy, patients' own immune systems become weapons in fighting cancer.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 国产精品观看在线亚洲人成网 | 免费特黄一级欧美大片 | 大桥未久在线精品视频在线 | 日本三级在线观看中文字 | 午夜三级网 | 久久狠| 91精品欧美综合在线观看 | 久久精品国产亚洲 | 91久久精一区二区三区大全 | 亚洲国产天堂久久综合网站 | 中文字幕一区二区精品区 | 看全黄男人和女人视频 | 国产精品久久久久久久久免费观看 | 久久久精品一区 | 99热播 | 国产猛烈无遮掩视频免费网站男女 | 精品一区二区三区在线观看l | 成人国产精品一级毛片视频 | 91年精品国产福利线观看久久 | 国产成人爱片免费观看视频 | 日韩在线播放视频 | 久久久久久免费播放一级毛片 | 国内自拍tv在线 | 狠狠狠狠狠 | 99综合在线| 日韩在线视精品在亚洲 | 婷婷91| 久久亚洲成a人片 | 午夜伦4480yy妇女久久久 | 国产成人精品久久一区二区小说 | 久久成人国产精品免费 | 久草在线新首页 | 韩国三级 mp4 | 日韩欧美~中文字幕 | 99视频网站| 日韩欧美精品在线观看 | 国产精品久久久久国产精品 | 日本高清视频www夜色资源 | 亚洲在线偷拍自拍 | 成人免费视频在线 | 天堂视频在线免费观看 |